Perindopril reduced cardiac events in stable coronary artery disease

March 2004
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p31
Academic Journal
The article focuses on the factors that help in reducing the cardiovascular events among patients with stable coronary artery disease. It examines if the angiotensin-converting enzyme (ACE) inhibitor perindopril reduce cardiac events in patients with stable coronary artery disease (CAD). Patients of different age-group were analyzed and were allocated to perindopril or placebo. It was found that fewer patients who received perindopril reached the primary composite endpoint than did patients who received placebo.


Related Articles

  • Perindopril reduced cardiac events in stable coronary artery disease: COMMENTARY. Best, Patricia J. M.; Berger, Peter R. // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p31 

    The article comments on the study of the efficacy of perindopril in reducing cardiac event in stable coronary artery diseases. The supported the widespread use of the angiotensin-converting enzyme (ACE ) inhibitor ramipril to prevent cardiovascular events. However, several questions remained and...

  • Cost of Heart Failure in Patients Receiving Î’ -Blockers and Angiotensin-Converting Enzyme Inhibitors. Weintraub, William S.; Kawabata, Hugh; Tran, Michele; L'Italien, Gilbert J.; Chen, Roland S. // Clinical Drug Investigation;2004, Vol. 24 Issue 5, p255 

    Objective: Numerous studies support the benefit of β-blockers and angiotensin-converting enzyme inhibition (ACE-I) in the management of heart failure. However, the real-world cost of heart failure in patients who take these medications is not well documented; furthermore, it is unclear if...

  • ACE Inhibitors after Myocardial Infarction: Clinical and Economic Considerations. Davie, A.P. // PharmacoEconomics;2000, Vol. 17 Issue 3, p237 

    Economic analysis has been extensively used to guide the use of ACE inhibitors in chronic heart failure. More recently, it has been used to guide the use of ACE inhibitors after myocardial infarction. The results of major clinical trials leave us in no doubt that ACE inhibitors are useful in the...

  • ACE inhibitor-ARB combination no benefit.  // Pulse;11/4/2009, Vol. 69 Issue 35, p9 

    The article reports on the systematic review which shows that there is no benefit on the combination of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) for treatment of ischaemic heart disease in Great Britain. It states that patients who are taking both medicines...

  • Baseline demographics of the Valsartan Heart Failure Trial. Cohn, Jay N.; Tognoni, Gianni; Glazer, Robert; Spormann, Dirk // European Journal of Heart Failure;Dec2000, Vol. 2 Issue 4, p439 

    Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale randomized, multinational clinical study to assess the efficacy and safety of valsartan, an angiotensin II receptor blocker, added to conventional therapy, including angiotensin-converting enzyme inhibitors, in...

  • Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention. Hamon, M.; Fradin, S.; Denizet, A.; Filippi-Codaccioni, E.; Grollier, G.; Morello, R. // Heart;Mar2003, Vol. 89 Issue 3, p321 

    Objective: To evaluate prospectively the influence of an angiotensin I converting enzyme (ACE) gene polymorphism on long term clinical outcome of patients with established coronary artery disease treated by percutaneous coronary intervention. Design and setting: Prospective observational study...

  • Lesser Response to Angiotensin-Converting—Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction. Exner, Derek V.; Dries, Daniel L.; Domanski, Michael J.; Cohn, Jay N. // New England Journal of Medicine;05/03/2001, Vol. 344 Issue 18, p1351 

    Background: Black patients with heart failure have a poorer prognosis than white patients, a difference that has not been adequately explained. Whether racial differences in the response to drug treatment contribute to differences in outcome is unclear. To address this issue, we pooled and...

  • The Association of Gene Polymorphisms of the Angiotensin-Converting Enzyme and Angiotensin II Receptor Type 1 with schemic Stroke in Turkish Subjects of Trakya Region. Sipahi, Tammam; Güldiken, Babürhan; Güldiken, Sibel; Üstündag, Sedat; Turgut, Nilda; Budak, Metin; Cakina, Suat; Özkan, Hülya; Şener, Seralp // Medical Journal of Trakya University / Trakya Universitesi Tip F;2009, Vol. 26 Issue 1, p1 

    Objectives: The aim of this study was to investigate the frequency of ACE insertion/deletion (I/D) and AT1R (A1166C) gene polymorphisms in ischemic stroke patients in Trakya region and the relation between these gene polymorphisms and stroke subtypes and vascular risk factors. Patients and...

  • Assessment of prognosis in chronic coronary artery disease. Bateman, T. M.; Prvulovich, E. // Heart;Aug2004 Supplement 5, Vol. 90, pv10 

    The article focuses on chronic coronary artery disease. For many patients with chronic coronary artery disease, risk stratification as to the likelihood of cardiac death lies at the basis of choosing between the two major therapeutic options of medical management or revascularisation. Perfusion...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics